Viruses (Feb 2023)

Administration of Bacteriophages via Nebulization during Mechanical Ventilation: In Vitro Study and Lung Deposition in Macaques

  • Sandrine Le Guellec,
  • Jeoffrey Pardessus,
  • Elsa Bodier-Montagutelli,
  • Guillaume L’Hostis,
  • Emilie Dalloneau,
  • Damien Piel,
  • Hakim Chouky Samaï,
  • Antoine Guillon,
  • Elvir Mujic,
  • Emmanuelle Guillot-Combe,
  • Stephan Ehrmann,
  • Eric Morello,
  • Jérôme Gabard,
  • Nathalie Heuzé-Vourc’h,
  • Cindy Fevre,
  • Laurent Vecellio

DOI
https://doi.org/10.3390/v15030602
Journal volume & issue
Vol. 15, no. 3
p. 602

Abstract

Read online

Bacteriophages have been identified as a potential treatment option to treat lung infection in the context of antibiotic resistance. We performed a preclinical study to predict the efficacy of delivery of bacteriophages against Pseudomonas aeruginosa (PA) when administered via nebulization during mechanical ventilation (MV). We selected a mix of four anti-PA phages containing two Podoviridae and two Myoviridae, with a coverage of 87.8% (36/41) on an international PA reference panel. When administered via nebulization, a loss of 0.30–0.65 log of infective phage titers was measured. No difference between jet, ultrasonic and mesh nebulizers was observed in terms of loss of phage viability, but a higher output was measured with the mesh nebulizer. Interestingly, Myoviridae are significantly more sensitive to nebulization than Podoviridae since their long tail is much more prone to damage. Phage nebulization has been measured as compatible with humidified ventilation. Based on in vitro measurement, the lung deposition prediction of viable phage particles ranges from 6% to 26% of the phages loaded in the nebulizer. Further, 8% to 15% of lung deposition was measured by scintigraphy in three macaques. A phage dose of 1 × 109 PFU/mL nebulized by the mesh nebulizer during MV predicts an efficient dose in the lung against PA, comparable with the dose chosen to define the susceptibility of the strain.

Keywords